Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07023666 · ClinicalTrials.gov registry record · Phase 2
Early Screening and Treatment of Heart Complication in Sickle Cell Disease
A Phase 2 study of Sickle Cell Disease, sponsored by Inova Health Care Services.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 100
- Enrollment target
- 2
- Study locations
NCT07023666 is a Phase 2 study of Sickle Cell Disease that is actively recruiting participants, run by Inova Health Care Services. The registered enrollment target is 100 participants, below the 292-participant average among 213 other Sickle Cell Disease trials with a reported enrollment target (66% lower). The trial reports 2 study locations across 1 state.
The verdict
NCT07023666, a Phase 2 study of Sickle Cell Disease, is actively recruiting participants, sponsored by Inova Health Care Services.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 100 participants
- Enrollment target
- 2
- Study locations
Study Summary
This study tests whether early heart screening and treatment for iron overload in subjects with sickle cell disease can prevent heart problems and reduce hospitalizations.
Conditions Studied
Interventions
- DRUG Deferoxamine
- DRUG Deferasirox
- DRUG Deferiprone
- DEVICE Echocardiography
- DEVICE Electrocardiogram (ECG)
Study Locations (2)
Virginia
- Inova Schar Cancer - Fairfax
- Inova Health Care Service - Falls Church
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2025-10-07 |
| Est. Completion | 2027-06-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07023666
The ClinicalTrials.gov registry entry for NCT07023666 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 292-participant average among 213 other Sickle Cell Disease trials with a reported enrollment target (66% lower). The listed sponsor is Inova Health Care Services, which has 75 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Sickle Cell Disease appearing as the primary indexed condition, and to 5 interventions - of which Deferoxamine is the first listed.
NCT07023666 reports 2 study locations spanning 1 distinct geographic area - top geographies include Virginia.
Frequently Asked Questions
What is clinical trial NCT07023666 about?
NCT07023666 is a clinical study titled "Early Screening and Treatment of Heart Complication in Sickle Cell Disease". This study tests whether early heart screening and treatment for iron overload in subjects with sickle cell disease can prevent heart problems and reduce hospitalizations.
What is the current status of trial NCT07023666?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 100 participants. The study started on 2025-10-07. Estimated completion is 2027-06-30.
What conditions does trial NCT07023666 study?
This clinical trial studies the following conditions: Sickle Cell Disease.
What interventions are being tested in trial NCT07023666?
The interventions under investigation include: Deferoxamine (DRUG), Deferasirox (DRUG), Deferiprone (DRUG), Echocardiography (DEVICE), Electrocardiogram (ECG) (DEVICE).
Who is sponsoring clinical trial NCT07023666?
This trial is sponsored by Inova Health Care Services, which has 75 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07023666 being conducted?
This trial has 2 study locations across Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Sickle Cell Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Sub-dissociative Dose Ketamine in Treatment of Vaso-occlusive Pain Event in Children and Young Adults
RECRUITING · Phase 2
-
Relationship Between Abnormal Myocardial Perfusion and Diastolic Dysfunction in Sickle Cell Disease Using PET
RECRUITING · Phase 2
-
Myeloablative Conditioning, Prophylactic Defibrotide and Haplo AlloSCT for Patients With Sickle Cell Disease
RECRUITING · Phase 2
-
A Study of Immune Suppression Treatment for People With Sickle Cell Disease or β-Thalassemia Who Are Going to Receive an Allogeneic Hematopoietic Cell Transplantation (HCT)
RECRUITING · Phase 2
-
A Phase 2/3 Study in Adult and Adolescent Participants With SCD
RECRUITING · Phase 2
-
Allo HSCT for High Risk Hemoglobinopathies
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.